Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Diastole

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43871   clinical trials with a EudraCT protocol, of which   7290   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    18 result(s) found for: Diastole. Displaying page 1 of 1.
    EudraCT Number: 2011-000805-27 Sponsor Protocol Number: MEIN/10/Ran-Did/001 Start Date*: 2012-10-23
    Sponsor Name:Menarini International Operations Luxembourg S.A., Avenue de la Gare, 1611 Luxembourg, Luxembourg
    Full Title: Effect of Ranolazine in Heart Failure Patients with Preserved Ejection Fraction
    Medical condition: Heart failure patients with preserved ejection fraction (HFpEF)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10019280 Heart failures HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-000285-35 Sponsor Protocol Number: Cardoz-003 Start Date*: 2011-05-09
    Sponsor Name:Cardoz AB
    Full Title: An international, multi-centre, randomised, stratified, double-blinded, placebo-controlled, 4-parallel group trial investigating the efficacy and safety of three different dose levels of CRD007 a...
    Medical condition: Abdominal aortic aneurysm (AAA) is a dilatation of the aorta as it passes through the abdomen, defined as a dilatation of the infra-renal aorta to a diameter of 30 mm. AAA is generally asymptom...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10047065 - Vascular disorders 10000054 Abdominal aortic aneurysm LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) GB (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2017-004521-32 Sponsor Protocol Number: D5780C00007 Start Date*: 2018-08-22
    Sponsor Name:MedImmune LLC, a wholly owned subsidiary of AstraZeneca PLC
    Full Title: A Randomized, Placebo-controlled Phase 2b Study to Evaluate the Safety and Efficacy of MEDI6012 in Acute ST Elevation Myocardial Infarction
    Medical condition: ST-elevation myocardial infarction
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10064345 ST segment elevation myocardial infarction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Completed) NL (Completed) CZ (Completed) SK (Completed) HU (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-000424-25 Sponsor Protocol Number: 1508175 Start Date*: 2016-04-12
    Sponsor Name:CHU Saint-Etienne
    Full Title: Low-molecular-weight heparin in constituted vascular intrauterine growth restriction. Randomized multicenter trial
    Medical condition: Intrauterine growth restriction (IUGR)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004868 10022819 Intrauterine growth retardation LLT
    20.0 100000004868 10048489 Intrauterine growth retard LLT
    20.0 100000004868 10048488 Growth intrauterine retard LLT
    Population Age: Adults Gender: Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-002931-95 Sponsor Protocol Number: LCC2010.01 Start Date*: 2008-01-30
    Sponsor Name:UZ Leuven
    Full Title: The Effects of Nitric Oxide for Inhalation on Myocardial Infarction Size.
    Medical condition: Myocardial Infarction
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10028596 Myocardial infarction PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Prematurely Ended) HU (Completed)
    Trial results: View results
    EudraCT Number: 2021-003020-32 Sponsor Protocol Number: A011-16 Start Date*: 2022-02-03
    Sponsor Name:Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ, USA
    Full Title: Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo-Controlled for the Treatment of Combined Postcapillary and Precapillary Pulmonary ...
    Medical condition: Combined Postcapillary and Precapillary Pulmonary Hypertension (Cpc-PH) due to Heart Failure with Preserved Ejection Fraction (HFpEF)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037400 Pulmonary hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing) DE (Ongoing) ES (Ongoing) IT (Ongoing) SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000713-32 Sponsor Protocol Number: CAEL101-302 Start Date*: 2020-12-23
    Sponsor Name:Alexion Pharmaceuticals, Inc.
    Full Title: A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dysc...
    Medical condition: stage IIIa cardiac AL amyloidosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10007509 Cardiac amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) GB (GB - no longer in EU/EEA) GR (Ongoing) PL (Ongoing) BE (Completed) AT (Ongoing) CZ (Ongoing) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005405-78 Sponsor Protocol Number: 2011430 Start Date*: 2012-02-01
    Sponsor Name:Steen Bendix Haugaard
    Full Title: Adding liraglutide to the backbone therapy of biguanide in patients with coronary artery disease and newly diagnosed type-2 diabetes
    Medical condition: Patients suffering of both Type 2 diabetes mellitus and coronary artery disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10011079 Coronary artery disease NOS LLT
    14.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-000518-34 Sponsor Protocol Number: 0107 Start Date*: 2011-10-25
    Sponsor Name:Rikshospitalet
    Full Title: Effect of beta blockade on left ventricular remodeling and function in aortic regurgitation
    Medical condition: The aim of the present study is therefore to assess the effect of a 6 month treatment with beta-blocker on left ventricular remodeling and function in patients with asymptomatic moderate to severe ...
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004849 10002904 Aortic regurgitation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-004318-14 Sponsor Protocol Number: NEOD001-201 Start Date*: 2016-06-13
    Sponsor Name:Prothena Therapeutics Limited
    Full Title: A Phase 2b, Randomized, Double-blind, Placebo-controlled Study of NEOD001 in Previously Treated Subjects with Light Chain (AL) Amyloidosis who have Persistent Cardiac Dysfunction
    Medical condition: Light chain (AL) amyloidosis involves a hematologic disorder caused by clonal plasma cells that produce misfolded immunoglobulin light chains. Overproduction of misfolded light chains results in bo...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10036673 Primary amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Completed) GR (Completed) ES (Prematurely Ended) AT (Completed)
    Trial results: View results
    EudraCT Number: 2014-003865-11 Sponsor Protocol Number: NEOD001-CL002 Start Date*: 2015-11-27
    Sponsor Name:Prothena Therapeutics Limited
    Full Title: A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care vs. Placebo Plus Standard of Care in Subjects with Light Chai...
    Medical condition: Light chain (AL) amyloidosis involves a hematologic disorder caused by clonal plasma cells that produce misfolded immunoglobulin light chains. Overproduction of misfolded light chains results in bo...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10036673 Primary amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended) ES (Completed) BE (Prematurely Ended) NL (Prematurely Ended) FR (Prematurely Ended) GB (Prematurely Ended) GR (Completed) PL (Prematurely Ended) DK (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-004254-28 Sponsor Protocol Number: CAEL101-301 Start Date*: 2021-01-07
    Sponsor Name:Caelum Biosciences, Inc.
    Full Title: A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dysc...
    Medical condition: stage IIIb cardiac AL amyloidosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10007509 Cardiac amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) DE (Ongoing) GB (GB - no longer in EU/EEA) GR (Ongoing) PL (Ongoing) BE (Ongoing) AT (Ongoing) CZ (Ongoing) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003626-24 Sponsor Protocol Number: MYK-491-006 Start Date*: 2020-04-06
    Sponsor Name:MyoKardia Inc.
    Full Title: An Open-Label, Exploratory Study of the Safety and Preliminary Efficacy of Danicamtiv in Stable Ambulatory Participants with Primary Dilated Cardiomyopathy Due to Either MYH7 or TTN Variants or Oth...
    Medical condition: Primary Dilated Cardiomyopathy Due to Either MYH7 or TTN Variants.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2013-002312-27 Sponsor Protocol Number: 13-031 Start Date*: 2013-08-14
    Sponsor Name:Zealand Pharma
    Full Title: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Assess Clinical Efficacy and Safety of Danegaptide in Patients with ST-Elevation Myocardial Infarction undergoing Primary Per...
    Medical condition: The treatment of acute myocardial infarction, AMI is aimed at enabling the return of blood flow to the ischemic myocardium, thereby limiting the size of the infarct. However the reperfusion by itse...
    Disease: Version SOC Term Classification Code Term Level
    16.1 10047065 - Vascular disorders 10063837 Reperfusion injury PT
    16.1 100000004849 10064345 ST segment elevation myocardial infarction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2018-004689-32 Sponsor Protocol Number: SHP675-301 Start Date*: 2021-09-24
    Sponsor Name:Shire Human Genetic Therapies, Inc.
    Full Title: A Phase 3, Open-label Study to Evaluate the Efficacy and Safety of REPLAGAL® in Treatment-naïve Subjects with Fabry Disease
    Medical condition: Fabry disease
    Disease: Version SOC Term Classification Code Term Level
    24.1 10010331 - Congenital, familial and genetic disorders 10016016 Fabry's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Ongoing) FI (Prematurely Ended) GR (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-013342-92 Sponsor Protocol Number: DSE-OLM-01-09 Start Date*: 2010-06-08
    Sponsor Name:DAIICHI SANKYO EUROPE GmbH
    Full Title: EFFECTS OF ANGIOTENSIN-RECEPTOR BLOCKADE WITH OLMESARTAN ON CAROTID ATHEROSCLEROSIS IN PATIENTS WITH HYPERTENSION: THE CONFIRMATORY OLMESARTAN PLAQUE REGRESSION STUDY (CONFIRM)
    Medical condition: Essential hypertension in subjects with documented carotid atherosclerosis
    Disease: Version SOC Term Classification Code Term Level
    12.0 10020772 Hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Prematurely Ended) IT (Prematurely Ended) CZ (Completed) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-006755-44 Sponsor Protocol Number: 2008-510 Start Date*: 2009-01-15
    Sponsor Name:HOSPICES CIVILS DE LYON
    Full Title: METAFORE : Maladie de Rendu-Osler : Etude de l’Efficacité et de la tolérance du Bevacizumab utilisé pour le traitement des formes hépatiques sévères. Etude de phase II
    Medical condition: Maladie de Rendu-Osler
    Disease: Version SOC Term Classification Code Term Level
    9.1 10031132 Osler-Weber-Rendu disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-000037-14 Sponsor Protocol Number: NEOD001-301 Start Date*: 2021-09-01
    Sponsor Name:Prothena Biosciences Limited
    Full Title: A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with ...
    Medical condition: AL amyloidosis involves a hematologic disorder caused by clonal plasma cells that produce misfolded immunoglobulin light chains. Overproduction of misfolded light chains results in both soluble, a...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10036673 Primary amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Ongoing) HU (Ongoing) DE (Ongoing) PT (Ongoing) PL (Ongoing) ES (Ongoing) GR (Ongoing) NL (Ongoing) IT (Ongoing) IE (Ongoing) AT (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 03 20:43:43 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA